Abstract
The vanilloid subfamily of transient receptor potential (TRPV) ion channels serves critical functions in sensory signaling in specialized cells and intact organisms ranging from yeast to primates. As thermosensors, chemosensors, and/or mechanosensors, these channels monitor the local environment and integrate and respond to multiple stimuli distinctively. More than a decade of research on the founding member of the subclass, TRPV1, has led to advancement of multiple antagonists into the clinic for the treatment of chronic pain. In recent years the comprehensive knowledge accessed through these studies has been applied to enhance understanding of other TRPV isoforms and, in particular, to determine whether they, too, represent promising targets for drug discovery. This review focuses on emerging data that define a role for TRPV3 in transducing signals in pain pathways and identify antagonists that demonstrate efficacy in relevant preclinical behavioral models.
Keywords: Antagonist, ion channel, pain, transient receptor potential, TRPV3, thermosensors, chemosensors, mechanosensors, multiple stimuli, multiple antagonists, chronic pain, TRPV isoforms, drug discovery, transducing signals in pain pathways, efficacy
Current Topics in Medicinal Chemistry
Title: Analgesic Potential of TRPV3 Antagonists
Volume: 11 Issue: 17
Author(s): Regina M. Reilly and Philip R. Kym
Affiliation:
Keywords: Antagonist, ion channel, pain, transient receptor potential, TRPV3, thermosensors, chemosensors, mechanosensors, multiple stimuli, multiple antagonists, chronic pain, TRPV isoforms, drug discovery, transducing signals in pain pathways, efficacy
Abstract: The vanilloid subfamily of transient receptor potential (TRPV) ion channels serves critical functions in sensory signaling in specialized cells and intact organisms ranging from yeast to primates. As thermosensors, chemosensors, and/or mechanosensors, these channels monitor the local environment and integrate and respond to multiple stimuli distinctively. More than a decade of research on the founding member of the subclass, TRPV1, has led to advancement of multiple antagonists into the clinic for the treatment of chronic pain. In recent years the comprehensive knowledge accessed through these studies has been applied to enhance understanding of other TRPV isoforms and, in particular, to determine whether they, too, represent promising targets for drug discovery. This review focuses on emerging data that define a role for TRPV3 in transducing signals in pain pathways and identify antagonists that demonstrate efficacy in relevant preclinical behavioral models.
Export Options
About this article
Cite this article as:
M. Reilly Regina and R. Kym Philip, Analgesic Potential of TRPV3 Antagonists, Current Topics in Medicinal Chemistry 2011; 11 (17) . https://dx.doi.org/10.2174/156802611796904889
DOI https://dx.doi.org/10.2174/156802611796904889 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autonomic Dysfunction in Diabetes: a Consequence of Cardiovascular Damage
Current Diabetes Reviews Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Restless Legs Syndrome After Single Low Dose Quetiapine Administration
Current Drug Safety Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry Docking Study of Novel Pyrrolidine Derivatives as Potential Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors
Letters in Drug Design & Discovery Synthesis, Structural Characterization and Docking Studies of Sulfamoyl- Phenyl Acid Esters as Dipeptidyl Peptidase-IV Inhibitors
Current Computer-Aided Drug Design Behcets Syndrome: Literature Review
Current Rheumatology Reviews The pH of Wound Fluid in Diabetic Foot Ulcers- the Way Forward in Detecting Clinical Infection?
Current Diabetes Reviews Pathogenesis and Treatment of Callus in the Diabetic Foot
Current Diabetes Reviews Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Management of Type 2 Diabetes: More Evidence is Required to Address the Clinical and Contextual Facets
Current Diabetes Reviews A Three-gene-based Type 1 Diabetes Diagnostic Signature
Current Pharmaceutical Design Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Identification of GCP II Inhibitors Based on 4-Arylmethyl-3-(4- carboxyphenyl)-5-hydroxyisoxazole Scaffold
Letters in Drug Design & Discovery Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Mini-Reviews in Medicinal Chemistry Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry